OptiTROP-Lung06 Trial Shows Superiority of Sacituzumab Tirumotecan Plus Pembrolizumab in NSCLC

Results from the randomized Phase III OptiTROP-Lung06 trial, presented at the ESMO Congress 2026, indicate that sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab significantly reduced the risk of progression or death by 51% compared to pembrolizumab plus platinum-pemetrexed chemotherapy in patients with PD-L1–negative advanced non-squamous non-small cell lung cancer (NSCLC). This suggests a new, more effective first-line treatment option for this patient population.